Sign in
Taking people in United StatesNo phase

Comparing nighttime settings of the Enterra device for people with gastroparesis

Compares nighttime Enterra device settings in people with gastroparesis.

Key facts

Who runs it
Enterra Medical, Inc.
Where
Coon Rapids and Louisville, United StatesSee the 2 sites
Trial code
Registry title
Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
Status
Recruiting
People taking part
50 people, planned
Started
10 Jul 2023
Planned end
Dec 2025
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Enterra® Therapy System
Record updated
15 November 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with gastroparesis (slow stomach emptying) who already have an Enterra® stomach stimulator implanted. It tests different device settings during sleep.

Age
18 to 70 years
Sex
All sexes
Disease stage
Gastroparesis, diabetic or not, with stable symptoms. People must be on stable medical therapy and stable extra nutrition support in the month before joining.
Earlier treatment
Must currently have the Enterra® Therapy System (Enterra® II 37800 neurostimulator). The device battery must have more than 9 months of expected life left, and the device must have been implanted less than 4 years ago.
Biomarker or test result
Enterra lead impedance must be below 700 Ohms at screening.

Main reasons for not taking part

  • Gastroparesis after stomach surgery, or other active stomach or gut disease that could explain the symptoms
  • Severe nausea or vomiting at night, or severe symptoms on waking
  • No regular sleep schedule
  • Pregnancy, or plans to become pregnant during the trial
  • Chemical dependency, or life expectancy under 1 year from conditions other than gut diseases

The registry criteria, word for word

Show all 23 criteriaShow less

Other criteria

  • In order to be eligible to participate in this study, a participant must meet all of the following criteria:
  • Completed informed consent process with signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Male or female, aged ≥18 or ≤70 at time of informed consent
  • Currently implanted with the Enterra® Therapy System (Enterra® II 37800 neurostimulator)
  • High GES output defined as remaining pulse generator expected life of > 9 months from enrollment and less than 4 years from the time of implant
  • Stable gastroparesis symptoms, in the opinion of the investigator
  • On stable medical therapy for gastroparesis symptoms
  • On stable supplemental nutritional support during the month prior to enrollment
  • English language comprehension to complete study-required assessments
  • Reliable access to internet-connected smart device(s) to complete study-required assessments; A participant who meets any of the following criteria will be excluded from participation in this study:
  • Post-surgical gastroparesis (e.g., fundoplication, Bilroth I or II) or other active stomach or gastrointestinal diseases disorders which could explain symptoms in the opinion of the investigator
  • Subjects, in the opinion of the investigator, with profound nausea and/or vomiting at night
  • Subjects, in the opinion of the investigator, with profound gastroparesis symptoms upon waking in the morning
  • Subjects without a regular and defined sleep schedule
  • Pregnancy, or subject that intends to become pregnant during participation in the study
  • Chemical dependency
  • Enterra lead impedance measurements ≥ 700 Ohms at screening visit
  • Life expectancy < 1 year from conditions other than GI diseases
  • Subjects with an underlying disease leading to follow-up by MRI outside of current MR conditional indications
  • Participation in other clinical studies
  • Subjects involved in current or past medical-related litigation
  • Subjects with cognitive impairment or other characteristic that would limit subject's ability to complete study requirements

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 70 years old?

Where in United States

  • MNGI Digestive Health, P.A.Coon Rapids, United StatesContact: Roxanne StrehloTaking people
  • University of LouisvilleLouisville, United StatesContact: Abigail Stocker, MDTaking people

About the trial

What the trial wants to find out

The purpose of this research study is to evaluate if different Enterra® device programming methods active during sleeping hours can maintain gastroparesis-related symptom relief and quality of life measures.

Read full original descriptionShow less

Participants in this study with existing Enterra® devices will be randomly assigned to one of three programming methods that will be active during sleep. Participants will answer daily questions about their gastroparesis symptoms on an application with their phone/tablet. Participants will answer quality of life questionnaires about their gastroparesis symptoms at study visits.

Participants will be involved in the study for up to six months after treatment assignment.

Programming parameters in the study are within currently approved labeling.

The 3 groups in the trial

  • Control Sleep CycleExisting treatment, for comparison

    Baseline device programming parameters will be used during study participation. No modification to Enterra® device programming will be in effect during waking or sleeping hours.

    Treatment: Enterra® Therapy System

  • Arm 1 Sleep CycleTreatment being tested

    Device programming parameters participants have at enrollment will be used during waking hours. During sleeping hours, the Enterra® device will cycle through modified programming over the course of 6 hours. Each hour, the Enterra® device will deliver 30 minutes of reduced stimulation, followed by 30 minutes of waking hours stimulation. At the end of the 6-hour sleep cycle, the Enterra® device will return to waking hours programming.

    Treatment: Enterra® Therapy System

  • Arm 2 Sleep CycleTreatment being tested

    Device programming parameters participants have at enrollment will be used during waking hours. During sleeping hours, the Enterra® device will cycle through modified programming over the course of 8 hours. Each hour, the Enterra® device will deliver 45 minutes of reduced stimulation, followed by 15 minutes of waking hours stimulation. At the end of the 8-hour sleep cycle, the Enterra® device will return to waking hours programming.

    Treatment: Enterra® Therapy System

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Randomized Study of Enterra Programming with Nocturnal Cycling in Gastroparetics
Plain-language title
Comparing nighttime settings of the Enterra device for people with gastroparesisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT05980455, who can take part
Record updated
15 November 2024